Program
ONO-4538HSC
A development code.
Its studies are mostly in Sarcoma, led by Ono Pharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Ono Pharmaceutical | 22 open or running | phase 2since Jul 6, 2026 | Jul 29, 2024 | Feb 29, 2028phase 1 · NCT06548217 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 29, 2024First study: phase 1 study in Advanced or Metastatic Solid TumorsFirst studyNCT06548217 · 31 enrolled · Japan
- Jul 6, 2026Phase 2 study in SarcomaPhase 2 reachedNCT07734116 · 50 planned · Japan
Ahead
- Feb 29, 2028Primary completion: phase 1 study in Advanced or Metastatic Solid TumorsNCT06548217
- Nov 30, 2029Primary completion: phase 2 study in SarcomaNCT07734116
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07734116Sarcoma · Japan | 2 | Recruiting | Nov 30, 2029 | 50 |
| NCT06548217Advanced or Metastatic Solid Tumors · Japan | 1 | Active, not recruiting | Feb 29, 2028 | 31 |
How it is read
Names in the registry
- “ONO-4538HSC”, 2 entries
Codes read as this program: ONO4538HSC.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.